Aster DM Quality Care: Emerging hospitals grow revenue 62%

Aster DM Quality Care Limited’s emerging hospitals increased revenue 62% year on year in H1FY27, while mature hospitals generated 83% of hospital operating earnings before interest, tax, depreciation and amortisation (operating EBITDA) from 64% of operational beds. Emerging-unit operating EBITDA margin rose 624 basis points to 16.3%, led by the ramp-up of Kasaragod and Nagercoil.

How concentrated are Aster DM Quality Care’s hospital earnings?

Aster DM Quality Care’s mature hospitals were the main hospital earnings contributor in H1FY27, producing 83% of operating EBITDA from 64% of operational beds. Defined as units more than three years old with operating EBITDA margins of at least 25%, mature hospitals accounted for 73% of hospital revenue and treated 2.99 million patients, up 11% year on year.

Mature-hospital revenue increased 18% and operating EBITDA increased 25% in H1FY27, lifting the margin by 186 basis points to 30.2%. The presentation attributes this change to patient volumes and case complexity. This margin was above the 26.6% reported for the hospital portfolio, which excludes corporate cost and adjacent businesses.

The other three maturity groups accounted for 36% of beds but 17% of operating EBITDA in H1FY27. Focus hospitals, defined as units older than three years with margins from 15% to 25%, increased revenue 13% and improved margin by 61 basis points to 18.6%. Under Performing hospitals held 11% of beds and generated 2% of operating EBITDA after a 722-basis-point margin increase to 12.1%.

Why did Aster DM Quality Care’s emerging hospitals grow 62%?

Aster DM Quality Care’s emerging hospitals grew H1FY27 revenue 62% because Kasaragod and Nagercoil ramped up faster, according to the presentation. The company defines emerging hospitals as units aged zero to three years; this group represented 10% of operational beds, treated 0.36 million patients and contributed 6% of hospital revenue.

Patient volumes at emerging hospitals rose 53% year on year, compared with a 13% increase across the hospital portfolio. Operating EBITDA increased 163%, and margin reached 16.3%, up 624 basis points. The presentation attributes the improvement to the faster ramp-up of Kasaragod and Nagercoil rather than identifying a segment-level pricing or capacity change.

Emerging hospitals generated 4% of operating EBITDA in H1FY27, below their 10% share of beds and 6% share of revenue. In Q2FY27, Aster DM Quality Care also said rapid turnaround at emerging units, through improved volumes and efficiencies, contributed to the group’s 25% operating EBITDA growth to Rs 678 crore.

What lifted Aster DM Quality Care’s mature-hospital margins?

Aster DM Quality Care said mature-hospital margin reached 30.2% in H1FY27 on higher patient volumes and case complexity. At group level in Q2FY27, revenue rose 19% to Rs 2,829 crore as total patients increased 12% to 2.18 million and operational beds increased 4% to 10,611.

Occupancy rose to 68% in Q2FY27 from 65% in Q2FY26, an increase of 335 basis points, while average length of stay was unchanged at 3.3 days. Management attributed the group operating-margin increase to operating leverage in material and other operating costs, higher patient footfall, complex procedures and a favourable payor mix. Operating EBITDA margin rose to 24.0% from 22.9%.

CONGO revenue increased 16% year on year in Q2FY27 and represented 53% of overall revenue. Within this category, robotic surgeries increased 39%, kidney transplants rose 31% and joint replacements grew 29%. Medical Value Travel revenue increased 36%, led by the Maldives and Gulf Cooperation Council markets, with rising contribution from West Africa and other Middle East and North Africa countries.

How did payors and specialties change at Aster DM Quality Care?

Aster DM Quality Care’s Q2FY27 payor mix shifted 2 percentage points from walk-in patients to third-party administrator payors. Walk-in revenue was 54%, down from 56% in Q2FY26, while third-party administrator revenue rose to 33% from 31%. Government health schemes remained at 9% and Medical Value Travel remained at 4%.

Specialty revenue mix was largely unchanged in Q2FY27, although orthopaedics increased to 9% from 8% a year earlier. Cardiac sciences declined to 15% from 16%, while oncology remained at 9%, neurosciences and gastroenterology each remained at 10%, and nephrology remained at 7%. Figures may not total 100% because of rounding.

Aster DM Quality Care added 66 doctors across its hospital network in H1FY27, which management said contributed about Rs 5 crore of monthly revenue. In Q2FY27, the company added one linear accelerator, one digital positron emission tomography-computed tomography scanner, three robots, two catheterisation laboratories and one magnetic resonance imaging machine. It reported investment of more than Rs 600 crore in medical technology over the preceding 18 months.

How did Aster DM Quality Care’s portfolio growth compare with group results?

Aster DM Quality Care’s hospital portfolio reported Rs 5,254 crore of H1FY27 revenue, up 19%, and Rs 1,398 crore of operating EBITDA, up 29%. The portfolio treated 4.14 million patients, up 13%, and had 10,611 operational beds as of September 30, 2026. These hospital-only figures exclude corporate cost, adjacent businesses and Wayanad Institute of Medical Sciences.

Consolidated revenue from operations was Rs 5,429 crore in H1FY27, up 20% from Rs 4,538 crore in H1FY26. Consolidated operating EBITDA increased 27% to Rs 1,255 crore, while the operating EBITDA margin increased to 23.1% from 21.8%. The difference from hospital-only measures reflects the presentation’s stated corporate-cost and business exclusions.

Normalised profit after tax increased 34% to Rs 281 crore in Q2FY27 from Rs 210 crore in Q2FY26. The presentation says the Q2FY27 measure excludes merger-related exceptional expenses and the share of loss of equity-accounted investees. Return on capital employed was 23.0% in Q2FY27, up 152 basis points, under the company’s stated calculation using EBITDA divided by average capital employed.

Conclusion

Aster DM Quality Care’s H1FY27 portfolio data shows that mature hospitals continued to provide most hospital earnings, with an 83% operating EBITDA share and a 30.2% margin. Emerging hospitals remained a smaller contributor at 4% of operating EBITDA, but their 62% revenue growth, 53% volume growth and 624-basis-point margin expansion added to portfolio growth.

The disclosed capacity plan calls for 4,230 additional beds, taking capacity from 10,840 to 15,070. The plan includes 454 beds in FY27, 1,330 in FY28, 770 in FY29 and 1,676 from FY30 and beyond; 47% of additions are planned in existing facilities and 53% in new facilities. The pace at which these additions ramp up, alongside mature-hospital margins, is the next disclosed portfolio measure to watch.